Renaissance Technologies
RUBY

Renaissance Technologies’s Rubius Therapeutics, Inc RUBY Stock Holding History

Renaissance Technologies’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-200,190
Closed -$35K – 4542
2022
Q4 		$35K Buy
200,190
+71,600
+56% +$19.6K ﹤0.01% 3867
2022
Q3 		$56K Sell
128,590
-697,868
-84% -$523K ﹤0.01% 3731
2022
Q2 		$703K Buy
826,458
+711,190
+617% +$1.19M ﹤0.01% 2942
2022
Q1 		$635K Buy
115,268
+44,314
+62% +$281K ﹤0.01% 3028
2021
Q4 		$687K Buy
70,954
+50,454
+246% +$700K ﹤0.01% 2920
2021
Q3 		$367K Buy
+20,500
New +$446K ﹤0.01% 3013
2021
Q2 		– Sell
-63,000
Closed -$1.67M – 3890
2021
Q1 		$1.67M Sell
63,000
-127,989
-67% -$1.87M ﹤0.01% 2334
2020
Q4 		$1.45M Sell
190,989
-73,739
-28% -$438K ﹤0.01% 2307
2020
Q3 		$1.33M Buy
264,728
+109,228
+70% +$579K ﹤0.01% 2352
2020
Q2 		$930K Buy
+155,500
New +$918K ﹤0.01% 2572

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Renaissance Technologies's RUBY Position: Q1 2023 in Review

Renaissance Technologies sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 200,190 shares — an estimated $35K sold.

Renaissance Technologies first reported a position in RUBY in Q2 2020 and held it in 10 quarters. The position peaked at $1.67M in Q1 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Renaissance Technologies reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Renaissance Technologies sold 200,190 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $35K.
  • Renaissance Technologies first reported a position in Rubius Therapeutics, Inc in Q2 2020 and held it in 10 quarters.
  • Renaissance Technologies's Rubius Therapeutics, Inc position peaked at $1.67M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.